PCSK9 Inhibitor
-
Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Promise in HeFH Phase 3 Trial
Merck announced positive Phase 3 CORALreef HeFH trial results for enlicitide, a once-daily oral PCSK9 inhibitor, at AHA 2025. The study demonstrated a significant 59.4% LDL-C reduction compared to placebo at week 24 in adults with HeFH. Enlicitide also showed improvements in other lipid parameters with a safety profile comparable to placebo. It is designed to deliver antibody-like efficacy, addressing unmet needs in HeFH patients and potentially becoming the first approved oral PCSK9 inhibitor. The results were published in the *Journal of the American Medical Association.*
